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A 29 year old para 1 was referred to the gynaecology clinic by her
general practitioner with symptoms of persistent and profuse, clear,
vaginal discharge for ten months following a vaginal delivery and sus-
picious speculum examination ﬁndings during a follow-up cervical
smear test. There was neither history of itch or offensive smell nor
any post coital or intermenstrual bleed. She was not using contracep-
tives and was trying for a pregnancy.
Relevant past obstetric history was presentation at 9 weeks of ges-
tation with unprovoked vaginal bleed. The cervix looked abnormal on
a speculum examination. Colposcopy revealed a normal cervix. A
follow-up post-natal smear test at the colposcopy clinic 8 weeks
after a spontaneous delivery again showed a normal cervix and
yielded a negative cervical smear. A follow-up smear 6 months later
was organised due to the previous borderline nuclear change in endo-
cervical cells. The GP referred the woman to the gynecology clinic
after ﬁnding an abnormal cervix when taking the smear.
At the gynecology clinic, a polypoid lesion was seen arising from
the cervix. An examination under anaesthesia was performed. This
showed a 5–6 cm mass, with copious mucus production, arising
from the cervix. Another 1–2 cm tumour was found at the lower 1/
3rd of the left lateral wall of the vagina. A clinical diagnosis of stage
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Open access under CC BY-NC-ND license.ﬁndings. A large loop biopsy of the cervical lesion and a punch biopsy
of the vaginal lesion were sent for histo-pathological examination.
Histology showed moderately differentiated papillary adenocarci-
noma with a villoglandular pattern (Fig. 1). The vaginal biopsy
showed mucin producing papillary adenocarcinoma (Fig. 2) of identi-
cal appearance conﬁrming a vaginal metastasis. There was no evi-
dence of lymphovascular space invasion.
An MRI showed a 4.2×2.5×4.6 cm tumour arising from the ante-
rior lip of the cervix, no parametrial involvement or signiﬁcant pelvic
or retroperitoneal lymph node enlargement. A 2.0×2.0 cm abnormal-
ity was seen in the left lower paravaginal space of different signal in-
tensity to the cervical primary, but presumed to be the vaginal
metastasis. A PET–CT scan showed increased FDG uptake on the
bulky cervical tumour. There was no nodal or distant metastasis.
The multi-disciplinary team meeting conﬁrmed a stage IIIA cancer
of the cervix and decided to treat with chemo-radiotherapy. She re-
ceived 45 Gy in 25 fractions of external beam radiotherapy to the pel-
vis with concomitant weekly cisplatin 40 mg/m2. The lower border of
the radiotherapy ﬁeld included the vaginal metastasis. Following
completion of external beam radiotherapy, she proceeded to low
dose rate brachytherapy (Henshcke application). The radiotherapy
dose to the primary cervical tumour was 26 Gy to point A, and the
lower vagina was included in the ﬁeld. At brachytherapy insertion,
the primary cervical tumour had responded well to the initial
chemo radiotherapy, however the para-vaginal metastasis was
unchanged.
Four weeks later there was persistent lower vaginal tumour with
clinical complete response of the cervical primary. She was therefore
referred for, and proceeded to, interstitial brachytherapy to the vagi-
nal metastasis and received 36 Gy in 6 fractions, receiving 2 fractions
a day for 3 days.
Currently, the patient had completed her interstitial brachythera-
py. After 4 months the vaginal lesion has completely responded.Discussion
Adenocarcinoma of the uterine cervix accounts for about 10% of
cervical cancer. Villoglandular papillary adenocarcinoma (VGA) of
cervix is an uncommon but well recognized histologic subtype of cer-
vical papillary adenocarcinoma usually affecting young women [1].
VGA was ﬁrst reported by Young and Scully in 1989, who de-
scribed three main histological features: exophytic proliferation, pap-
illary architecture and mild to moderate cellular atypia [2]. Their
paper, albeit a small series, suggested that given the excellent prog-
nosis and the predominance of young patients, this tumour may be
Fig. 1. Cervical loop specimen showing adenocarcinoma with villoglandular pattern.
Fig. 2. Vaginal biopsy showing similar villoglandular pattern.
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tumour is superﬁcial, has been completely excised, does not exhibit
vascular space invasion, and close follow-up is possible.
Conﬂicting conclusions on the prognosis of villoglandular adeno-
carcinoma have been reported in various case series, most of them
quoting excellent prognosis [2-4] with few reporting rapid deteriora-
tion [1,5].
The standard treatment for advanced adeno-squamous cervical
cancer is chemo radiation. As our patient had a stage IIIA villoglandu-
lar papillary adenocarcinoma, fertility sparing surgery was not an
option.
External beam radiotherapy with concomitant cisplatin chemo-
therapy, followed by intracavitary brachytherapy application pro-
duced no response in the vaginal skip metastasis. To boost the
radiotherapy dose to this area, interstitial brachytherapy was used
to the vaginal lesion which resulted in good response.To the best of our knowledge, this is the ﬁrst case report of a villo-
glandular adenocarcinoma of the cervix that presented with a skip le-
sion to the vagina without other evidence of regional or distant
disease. This report adds to the literature that rarely these tumours
can have aggressive behaviour, thus this should be considered in
the choices for therapy especially if considering fertility sparing treat-
ment options.
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